Pre- and postsynaptic inhibitory potencies of the angiotensin AT 1 receptor antagonists eprosartan and candesartan

By Nap A.   Mathy M.-J.   Balt J.C.   Pfaffendorf M.   van Zwieten P.A.  

European Journal of Pharmacology, Vol. 469, Iss. 1, 2003-05 ,pp. : 117-124

Elsevier

Access to resources Recommend Favorite

Candesartan: widening indications for this angiotensin II receptor blocker?

By Mendis B   Page SR  

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 12, 2009-08 ,pp. : 1995-2007

Informa Healthcare

Access to resources Recommend Favorite

Binding of the antagonist [ 3 H]candesartan to angiotensin II AT 1 receptor-tranfected Chinese hamster ovary cells

By Fierens F.   Vanderheyden P.M.L.   De Backer J.-P.   Vauquelin G.  

European Journal of Pharmacology, Vol. 367, Iss. 2, 1999-02 ,pp. : 413-422

Elsevier

Access to resources Recommend Favorite

In vitro effect of sanguinarine alkaloid on binding of [ 3 H]candesartan to the human angiotensin AT 1 receptor

By Caballero-George C.   Vanderheyden P.M.L.   Solis P.N.   Gupta M.P.   Pieters L.   Vauquelin G.   Vlietinck A.  

European Journal of Pharmacology, Vol. 458, Iss. 3, 2003-01 ,pp. : 257-262

Elsevier

Access to resources Recommend Favorite

Effects of the insurmountable angiotensin AT 1 receptor antagonist candesartan and the surmountable antagonist losartan on ischemia/reperfusion injury in rat hearts

By Wang Q.-D.   Sjoquist P.-O.  

European Journal of Pharmacology, Vol. 380, Iss. 1, 1999-09 ,pp. : 13-21

Elsevier

Access to resources Recommend Favorite